A three-part protein fragment sold for blood-vessel health. In laboratory dishes and aged animal tissue the idea holds up; in people it rests on small studies without comparison groups, all run by the institute that created, patented and sells it. Outside Russia supply comes from sellers stating it is not for human use, with contents often unlike the label. (Full Review)

Protocol

Standard oral course (Russian supplement protocol)

1–2 capsules of 0.1 mg peptide complex, once or twice daily

30 minutes before food, for 10–30 consecutive days, repeated two to three times a year

Time of day

Morning, before food

The published instruction; no chronobiology data exist. The sublingual form is taken away from meals for the same absorption reason

Competing approach — subcutaneous research vials

No published human protocol

Western users reconstitute 20 mg freeze-dried vials and inject small daily doses; the animal work used abdominal-cavity dosing at 400 µg/kg

Time to effect

End of a full 10–30 day course

The vascular series compared flow before and after that completed course; nothing in the literature supports a perceptible effect within days

Course-based, not lifelong

Discrete 10–30 day courses

Repeated a few times a year; no protocol anywhere, vendor or academic, describes indefinite daily intake

Cycling

Effects stated to persist beyond dosing

The stated rationale is that effects on gene expression outlast the dosing window, a claim no washout study has tested

Benefits

Low: Peripheral arterial blood flow in atherosclerotic vascular insufficiency; slowed biological-age drift in older adults with multiple chronic conditions; memory and attention in older adults with functional brain disorders; psychoemotional resilience under sustained occupational strain; oral mucosal recovery after cancer treatment

Speculative: Endothelial cell renewal and signalling in aged and atherosclerotic vessels; preservation of dendritic spines in an Alzheimer's mouse model; neuronal differentiation and serotonin signalling in aged nerve-cell cultures; delay of cellular senescence markers in human stem cells and skin fibroblasts; protection against low oxygen and oxidative membrane damage

Contraindications

Active or recent malignancy: cancer treated within the past 5 years, or an untreated pre-cancerous lesion

Pregnancy and lactation

Age under 18

Solid-organ transplant recipients on immunosuppression

Advanced kidney or liver failure (estimated filtration rate below 30 mL/min/1.73 m², or Child-Pugh Class C)

Known hypersensitivity to peptide preparations

Anyone unable to obtain a batch certificate of analysis

Key Interactions

Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, apixaban, warfarin)

Blood-pressure medicines (lisinopril, losartan, amlodipine)

Erectile-dysfunction drugs (sildenafil, tadalafil)

Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin)

Over-the-counter decongestants (pseudoephedrine, phenylephrine)

Supplements that widen vessels (L-Citrulline, beetroot nitrate, garlic extract)

Supplements affecting clotting (fish oil, nattokinase, Ginkgo biloba, vitamin E)

Other interventions (statins, sauna, blood-flow-restriction training)

Risk & Side Effects

Low: Substandard, mislabelled and endotoxin-contaminated product from the research-chemical channel; oxidant-promoting shift and suppressed blood-cell production

Speculative: Proliferative risk from suppressing cellular ageing brakes; injection-site reaction and immune response with reconstituted vials; unknown long-term, carcinogenicity and reproductive safety

Monitoring

Marker	Target	Why
Apolipoprotein B	< 60 mg/dL for aggressive prevention; < 80 mg/dL otherwise	Best single count of artery-clogging particles
Lipoprotein(a)	< 30 mg/dL (< 75 nmol/L)	Inherited vascular risk this compound cannot plausibly move
High-sensitivity C-reactive protein	< 0.8 mg/L	Vessel-wall inflammation, the plausible target of an endothelial agent
Fasting insulin	2–5 µIU/mL	Insulin resistance is a primary driver of vessel-lining dysfunction
Haemoglobin A1c	4.8–5.4%	Glucose-driven damage to the vessel wall over the prior three months
Complete blood count with differential	Within the laboratory reference range and not falling from personal baseline	The one human harm signal reported for this compound was suppressed blood-cell production
Homocysteine	5–7 µmol/L	Direct toxicity to the vessel lining, and a modifiable input
Blood pressure, home average	< 120/75 mmHg	The functional readout of vessel tone
Carotid intima–media thickness	Below the 50th percentile for age and sex	Structural vessel ageing — the outcome the compound claims to address
Ankle–brachial index	1.00–1.30	Detects narrowing in the leg arteries, the population actually studied
Carotid–femoral pulse-wave velocity	< 7.5 m/s under age 50; < 10 m/s over 60	Arterial stiffness, the most direct measure of vascular age
Estimated glomerular filtration rate	> 90 mL/min/1.73 m²	Kidney filtration mirrors the health of the smallest vessels

Cadence: Blood count and inflammatory markers at four weeks of the first course, the full panel at three months, then every six to twelve months; structural imaging repeated no more often than every one to two years.

Qualitative Assessment

Exercise tolerance and recovery time after a standard effort
Walking distance before calf pain begins, where peripheral disease is present
Cold hands and feet, and how quickly colour returns after cold exposure
Sexual function, the endpoint of the single human vascular study
Energy through the afternoon, and cognitive clarity on familiar tasks
Sleep quality and morning restedness

Vesugen for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment